

EXTRAORDINARY GENERAL MEETING

Thursday, 26 June 2025

Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses



	Allo CAR T Cell Therapy				CF33 Oncolytic Virus	
	azer-cel CD19 allo CAR T Phase 1b		onCARlytics CD19 expressing virus Phase 1 OASIS Trial		CF33 Oncolytic Virus Phase 1 VAXINIA MAST Trial	
	Off-the-shelf drug, aka allogeneic CAR T targeting blood cancers		Novel virus which acts as a CD19 target in solid cancers		Novel cancer killing virus	
•	57% complete response; best overall durability at >14 months and on going		Makes solid cancers visible to CD19 drugs	•	Targeting a range of late-stage solid cancers	
•	Anticipate to initiate Pivotal Phase 2/3 registrational trial in CY2026 (subject to data and regulatory approvals) – FDA meeting expected in late 2025	•	Currently in Phase 1 in solid cancers in combination with Blinatumomab (Approved CD19 drug in blood cancers)		Encouraging results in bile tract cancer and durable stability of disease	
•					FDA IND	
	FDA IND		FDA IND			

- Manufacturing: Out-Licensed azer-cel Phase 1b product to Kincell along with CAR T engineers to off-set cost and headcount
- Business and Development: Partnering/Out-licensing Opportunity is ongoing
- IR Conference Presentations: Dr. Jakob Dupont will be the keynote speaker at the Biotech Summit, E&P and Bell Potter's Healthcare conferences
- Potential Science Conferences: Targeting AACR, ASCO, LUGANO, SNO, ASH, SITC etc.
- Cost Control: Head count reductions, prioritizing programs for value impacting studies are on-going



ASX:IMU

Thank You For Attending

